Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia

Psychopharmacology Bulletin

Volumn 34, Issue 1, 1998, Pages 61-69

  Daniel, David G ^a   Wozniak, Patricia ^b   Mack, Randall J ^b   McCarthy, Bruce G ^b  

^a Clinical Studies Ltd   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Extrapyramidal symptoms; Neuroleptics; Relapse; Schizophrenia; Sertindole

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; SERTINDOLE;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; IMIDAZOLES; INDOLES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 0031954462     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. American Psychiatric Association, Committee on Nomenclature and Statistics. DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders. 3d ed, revised. Washington, DC: American Psychiatric Association, 1987.
2. American Psychiatric Association, Committee on Nomenclature and Statistics. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
3. Andreasen, NC. Negative symptoms in schizophrenia: Definition and reliability. Arch. Gen. Psychiatry 39:784-788, 1982.
4. Ayd, FJ Jr. The depot fluphenazines: A reappraisal after 10 years' clinical experience. Am. J. Psychiatry 132(5):491-500, 1975.
5. Balon, R, and Berchou, R. Hematologic side effects of psychotropic drugs. Psychosomatics 27(2):119-127, 1986.
6. Bernstein, JG. Psychotropic drug-induced weight gain: Mechanisms and management. Clin. Neuropharmacology 11(Suppl. 1):S194-S206, 1988.
7. Bustillo, JR; Buchanan, RW; Irish, D; and Breier, A. Differential effect of clozapine on weight: A controlled study. Am. J. Psychiatry 153(2):817-819, 1996.
8. Cutler, N; Zolnouni, PP; O'Neil, JM; and Mack, RJ. Safety of antipsychotic drugs in elderly patients with dementia: Focus. Clin. Geriatr., submitted 1997.
9. Ereshefsky, L, and Nabulsi, A. Association of sertindole with reduction in health-care resource use by patients with schizophrenia. J. Clin. Psychiatry, submitted 1997.
10. Gerlach, J, and Casey, DE. Drug treatment of schizophrenia: Myths and realities. Curr. Opin. Psychiatry 7:65-70, 1994.
11. Goodpastor, WA, and Hare, BK. Factors associated with multiple readmissions to an urban public psychiatric hospital. Hosp. Community Psychiatry 42:85-87, 1991.
12. Guy, W. ECDEU Assessment Manual for Psychopharmacology. DHEW Pub. No. (ADM)76-338. Rockville, MD: National Institute of Mental Health, 1976.
13. Hummer, M; Kemmler, G; Kurz, M; Kurzthaler, I; Oberbauer, H; and Fleischhacker, WW. Weight gain induced by clozapine. Eur. Neuropsychopharmacol. 5:437-440, 1995.
14. Kane, JM; Casey, DE; Daniel, DG; and Newcomer, JW. Antipsychotic agents: minimizing side effects to maximize compliance. J. Clin. Psychiatry 57 (10):Suppl. 1-12, 1996.
15. Kay, SR; Fiszbein, A; and Opler, LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 13:261-276, 1987.
16. McEvoy, J; Borison, R; Small, J; van Kammen, D; Meltzer, H; Hamner, M; Morris, D; Shu, V; Sebree, T; and Grebb, J. The efficacy and tolerability of sertindole in schizophrenic patients: A pilot, double-blind, placebo-controlled, dose-ranging study. Schizophr. Res. 9:244, 1993.
17. National Institute of Mental Health. Special feature: Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol. Bull. 21(4), 1985.
18. Overall, JE, and Gorham, DR. Introduction - The Brief Psychiatric Rating Scale (BPRS): Recent developments in ascertainment and scaling. Psychopharmacol. Bull. 24:97-99, 1988.
19. Overall, JE, and Gorham, DR. The Brief Psychiatric Rating Scale. Psychol. Reports 10:799-812, 1962.
20. Potkin, SG; Targum, SD; Zborowski, BSN; Wozniak, P; and Kashkin, KB. Comparative efficacy and safety of sertindole and haloperidol in patients with schizophrenia. Arch. Gen. Psychiatry, submitted 1997.
21. Ryan, PM. Epidemiology, etiology, diagnosis, and treatment of schizophrenia. Am. J. Hosp. Pharm. 48:1271-1280, 1991.
22. Rupp, A, and Keith, SJ. The costs of schizophrenia: Assessing the burden. Psychiatr. Clin. North Am. 16(2):412-423, 1993.
23. Sanchez, C; Arnt, J; Dragsted, N; Hyttel, J; Lembol, HL; Meier, E; Perregaard, J; and Skarsfeldt, T. Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug. Dev. Res. 22:239-250, 1991.
24. SAS Institute, Inc. SAS User's Guide: Statistics. Version 6. Cary, NC: SAS Institute, Inc, 1991.
25. Skarsfeldt, T. Electrophysical profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurons in rats: Acute and repeated treatment. Synapse 10:25-33, 1992.
26. Stanton, JM. Weight gain associated with neuroleptic medication: A review. Schizophr. Bull. 21:463-472, 1995.
27. van Kammen, DP; McEvoy, JP; Targum, SD; Kardatzke, D; and Sebree, TB. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 124:168-175, 1996.
28. Zimbroff, DL; Kane, JM; Tamminga, CA; Daniel, DG; Mack, RJ; Wozniak, PJ; Sebree, TB; Wallin, BA; Kashkin, KB; and the Sertindole Study Group. A controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am. J. Psychiatry 154(6):782-791, 1997.